176 related articles for article (PubMed ID: 33860071)
21. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
[TBL] [Abstract][Full Text] [Related]
22. Plasma Biomarkers of Alzheimer Disease in Women With and Without HIV.
Li X; Yucel R; Clervius H; Kamalakar K; Zetterberg H; Blennow K; Zhang J; Adimora A; Collins LF; Fischl M; Kassaye S; Maki P; Seaberg E; Sharma A; Vance D; Gustafson DR
JAMA Netw Open; 2023 Nov; 6(11):e2344194. PubMed ID: 38019518
[TBL] [Abstract][Full Text] [Related]
23. Association of Neurofilament Light Chain, [
Palleis C; Franzmeier N; Weidinger E; Bernhardt AM; Katzdobler S; Wall S; Ferschmann C; Harris S; Schmitt J; Schuster S; Gnörich J; Finze A; Biechele G; Lindner S; Albert NL; Bartenstein P; Sabri O; Barthel H; Rupprecht R; Nuscher B; Stephens AW; Rauchmann BS; Perneczky R; Haass C; Brendel M; Levin J; Höglinger GU
Neurology; 2024 Jan; 102(1):e207901. PubMed ID: 38165362
[TBL] [Abstract][Full Text] [Related]
24. Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study.
Perna L; Stocker H; Burow L; Beyer L; Trares K; Kurz C; Gürsel S; Holleczek B; Tatò M; Beyreuther K; Mons U; Gerwert K; Perneczky R; Schöttker B; Brenner H
Alzheimers Res Ther; 2023 Nov; 15(1):198. PubMed ID: 37951931
[TBL] [Abstract][Full Text] [Related]
25. Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI.
Gill J; Latour L; Diaz-Arrastia R; Motamedi V; Turtzo C; Shahim P; Mondello S; DeVoto C; Veras E; Hanlon D; Song L; Jeromin A
Neurology; 2018 Oct; 91(15):e1385-e1389. PubMed ID: 30209234
[TBL] [Abstract][Full Text] [Related]
26. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients.
Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M
Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060
[TBL] [Abstract][Full Text] [Related]
27. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
Res Sq; 2024 Mar; ():. PubMed ID: 38562890
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
29. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.
Salvadó G; Larsson V; Cody KA; Cullen NC; Jonaitis EM; Stomrud E; Kollmorgen G; Wild N; Palmqvist S; Janelidze S; Mattsson-Carlgren N; Zetterberg H; Blennow K; Johnson SC; Ossenkoppele R; Hansson O
Alzheimers Dement; 2023 Jul; 19(7):2943-2955. PubMed ID: 36648169
[TBL] [Abstract][Full Text] [Related]
30. Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology.
Berry K; Asken BM; Grab JD; Chan B; Lario Lago A; Wong R; Seetharaman S; LaHue SC; Possin KL; Rojas JC; Kramer JH; Boxer AL; Lai JC; VandeVrede L
Alzheimers Dement (Amst); 2022; 14(1):e12321. PubMed ID: 35845260
[TBL] [Abstract][Full Text] [Related]
31. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
[TBL] [Abstract][Full Text] [Related]
32. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.
Yang Z; Sreenivasan K; Toledano Strom EN; Osse AML; Pasia LG; Cosme CG; Mugosa MRN; Chevalier EL; Ritter A; Miller JB; Cordes D; Cummings JL; Kinney JW
Alzheimers Res Ther; 2023 Nov; 15(1):190. PubMed ID: 37924152
[TBL] [Abstract][Full Text] [Related]
33. Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: The cardiovascular health study.
Cronjé HT; Liu X; Odden MC; Moseholm KF; Seshadri S; Satizabal CL; Lopez OL; Bis JC; Djoussé L; Fohner AE; Psaty BM; Tracy RP; Longstreth WT; Jensen MK; Mukamal KJ
Alzheimers Dement; 2023 Dec; 19(12):5672-5680. PubMed ID: 37392405
[TBL] [Abstract][Full Text] [Related]
34. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
[TBL] [Abstract][Full Text] [Related]
36. Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia.
Silva-Spínola A; Lima M; Leitão MJ; Bernardes C; Durães J; Duro D; Tábuas-Pereira M; Santana I; Baldeiras I
Eur J Neurol; 2023 Jun; 30(6):1565-1573. PubMed ID: 36880887
[TBL] [Abstract][Full Text] [Related]
37. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
38. Blood Markers in Relation to a History of Traumatic Brain Injury Across Stages of Cognitive Impairment in a Diverse Cohort.
LoBue C; Stopschinski BE; Saez Calveras N; Douglas PM; Huebinger R; Cullum CM; Hart J; Gonzales MM
J Alzheimers Dis; 2024; 97(1):345-358. PubMed ID: 38143366
[TBL] [Abstract][Full Text] [Related]
39. Plasma Alzheimer's biomarkers and brain amyloid in Hispanic and non-Hispanic older adults.
Asken BM; Wang WE; McFarland K; Arias F; Fiala J; Velez-Uribe I; Mayrand RP; Sawada LO; Freytes C; Adeyosoye M; Marsiske M; Rosselli M; Barker WW; Curiel Cid R; Loewenstein DA; DeKosky ST; Armstrong MJ; Smith GE; Adjouadi M; Vaillancourt DE; Duara R
Alzheimers Dement; 2024 Jan; 20(1):437-446. PubMed ID: 37671801
[TBL] [Abstract][Full Text] [Related]
40. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
